Baudax Bio is a pharmaceutical company primarily focused on commercializing and developing products for hospital and related acute care settings. Co. has launched its commercial product, ANJESO in the U.S. ANJESO is an intravenous analgesic agent. ANJESO is a cyclooxygenase-2 preferential, non-steroidal anti-inflammatory, or NSAID for the management of moderate to severe pain, which can be administered alone or in combination with other non-NSAID analgesics. Co.'s pipeline also includes other earlier stage product candidates including intermediate and short-acting neuromuscular blocking agents, and accompanying reversal agents that Co. is developing for use in hospital or related settings. The BXRX average annual return since 2019 is shown above.
The Average Annual Return on the BXRX average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BXRX average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BXRX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|